TMA Scorer
Looking to enter your results for a CPQA-AQCP survey? Head over to TMA Scorer.
| December 2023 | Run 222 Calretinin Run 223 IDH1 & ATRX Run 224 1p19q FISH Run 225 p53 vulvar |
| January 2024 | Run 226 Breast HER2 IHC with emphasis on HER2-low (free participation courtesy of AstraZeneca) Run 227 p63/AMACR/HMWCK Run 228 gHER2 ISH Run 229 gHER2 IHC |
| February 2024 | Run 230 HMB45 Run 231 PD-L1 (technical) Run 232 (MMR) |
| March 2024 | Run 233 H&E Run 234 HSV Run 235 ER/PR breast |
| April 2024 | Run 236 c-MYC lymphomas Run 237 pan-TRK IHC |
| May 2024 | Run 238 BRAFV600E IHC Run 239 ROS1 IHC (technical) Run 240 ALK ISH |
| June 2024 | Run 241 Chromogranin A Run 242 gHER2 IHC Run 243 Breast HER2 IHC with emphasis on HER2-low (free participation courtesy of AstraZeneca) ***p53 endo has been rescheduled to Oct (tentative)*** |
| July 2024 | Run 244 p16 Run 245 CK20 |
| August 2024 | Run 246 CD117 Run 247 PD-L1 (technical) Run 248 breast HER2 ISH |
| September 2024 | Run 249 CD20 Run 250 H&E Run 251 Synaptophysin Run 252 ALK IHC (lung) Run M3 CRC |
| October 2024 | Run 253 ER/PR breast Run 254 Ki67 Run 255 p53 endo ***BRAFV600E melanoma (postponed until Dec 2024) |
| November 2024 (surveys may be impacted by the ongoing Canada Post strike) | Run 256 IDH1 R132H and ATRX Run 257 1p19q FISH |
| December 2024 | Run 258 Calretinin Run 259 BRAFV600E melanoma Run 260 Breast HER2 IHC with emphasis on HER2-low (free participation courtesy of AstraZeneca) Run 261 p53 vulvar Run 262 PRAME |
